5 completed, 5 recruiting, 2 terminated, 1 active not recruiting. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 3, Terminated 2, Active not recruiting 1, Completed 1, Withdrawn 1 |
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Sarcoma, Myeloid: new trials by email Literature Review of Sarcoma, Myeloid trials Research Report on Sarcoma, Myeloid
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Musculoskeletal Ultrasound in Patients With Hematologic Malignancies Hematologic Neoplasms, Leukemia | Not yet recruiting | Assiut University | 50 | 2026-09-01 | 2026-08-25 | |
| VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma VAM_GROUP - Acute Myeloid Leukemia, Myeloid Sarcoma | Phase 2 | Recruiting | Ruijin Hospital | 48 | 2025-06-20 | 2025-07-09 |
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement Acute Myeloid Leukemia, Myelodysplastic Neoplasm | Recruiting | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 50 | 2024-01-20 | 2024-07-22 | |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML Ziftomenib, Venetoclax, Azacitidine - Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation | Phase 1 | Recruiting | Kura Oncology, Inc. | 420 | 2023-07-18 | 2026-03-13 |
| Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms Cladribine, Cytarabine, Mitoxantrone - Acute Biphenotypic Leukemia, Acute Myeloid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Washington | 62 | 2022-02-04 | 2026-04-17 |
| Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes retrospective data analysis - Acute Myeloid Leukemia | Completed | King Hussein Cancer Center | 32 | 2020-10-01 | 2021-09-27 | |
| Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers Cladribine, Cytarabine, Dexrazoxane Hydrochloride - Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 100 | 2018-09-19 | 2026-05-22 |
| Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Anti-thymocyte globulin (rabbit), Blinatumomab, Cyclophosphamide - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Active not recruiting | St. Jude Children's Research Hospital | 170 | 2016-07-14 | 2025-08-12 |
| Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia Cytarabine, Vosaroxin - Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Completed | Vanderbilt-Ingram Cancer Center | 42 | 2016-03-01 | 2025-04-15 |
| CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Hematopoietic Cell Transplantation - Granulocytic Sarcoma, Recurrent Adult Acute Myeloid Leukemia | Phase 1 | Completed | Wake Forest University Health Sciences | 48 | 2015-09-01 | 2024-09-19 |
| Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation Cyclophosphamide, Fludarabine, G-CSF - Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | St. Jude Children's Research Hospital | 12 | 2014-10-01 | 2017-05-30 |
| T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant clofarabine, cytarabine, busulfan - Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia | Phase 2 | Terminated | St. Jude Children's Research Hospital | 34 | 2012-08-01 | 2017-02-20 |
| Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Asparaginase, Bortezomib, Cytarabine - Acute Myeloid Leukemia, Leukemia Cutis | Phase 3 | Completed | National Cancer Institute (NCI) | 1645 | 2011-07-06 | 2026-06-02 |
| PET-CT in AML for Detection of Extramedullary AML Manifestations Newly Diagnosed or Relapsed Acute Myeloid Leukemia | Completed | Technische Universität Dresden | 93 | 2011-02-01 | 2013-09-18 |
Leukemia, Myeloid, Acute (14) · Hematologic Neoplasms (4) · Leukemia (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (3) · Leukemia, Myelomonocytic, Juvenile (3) · Lymphoma, Non-Hodgkin (3) · Myelodysplastic Syndromes (3) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Anemia, Refractory, with Excess of Blasts (1) · Blast Crisis (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma (1) · Multiple Myeloma (1)
Hematologic Diseases (15) · Hemic and Lymphatic Diseases (15) · Leukemia, Myeloid (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms, Connective and Soft Tissue (15) · Sarcoma (15) · Leukemia (12) · Bone Marrow Diseases (5) · Chronic Disease (5) · Disease Attributes (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5)
Cytarabine (7) · Cyclophosphamide (3) · Mitoxantrone (3) · Cladribine (2) · Daunorubicin (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Melphalan (2) · Rituximab (2) · Tacrolimus (2) · Thiotepa (2) · devimistat (2) · fludarabine (2) · fludarabine phosphate (2) · thymoglobulin (2)
St. Jude Children's Research Hospital (3) · Wake Forest University Health Sciences (2) · Assiut University (1) · King Hussein Cancer Center (1) · Kura Oncology, Inc. (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Ruijin Hospital (1) · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (1) · Technische Universität Dresden (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1)
United States (9) · China (2) · Australia (1) · Canada (1) · Germany (1) · Jordan (1) · New Zealand (1) · Puerto Rico (1)
Brandon Triplett, MD (2) · Bayard Powell (1) · Bayard Powell, MD (1) · Brandon M. Triplett, MD (1) · Maro Ohanian (1) · Mary-Beth M. Percival (1) · Michael Savona, MD (1) · Richard Aplenc (1) · Sanjay Mohan, MD (1) · Xianmin Song, MD (1)
PMID 21685468, PMID 28419486, PMID 30773463, PMID 30987448, PMID 32029509, PMID 33213985, PMID 34596937, PMID 34855461, PMID 35349331, PMID 35354808, PMID 36815378, PMID 37267439, PMID 38295280, PMID 40294366, PMID 40535475, PMID 42085603, PMID 42227701
P30CA012197 (2), P30CA016672 (1), P30CA068485 (1), U10CA098543 (1), U10CA180886 (1)